Navigation Links
Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
Date:11/8/2007

- Conference Call and Webcast on November 9 at 8:00 a.m. PST -

SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today reported financial results for the three and nine months ended September 30, 2007.

"Halozyme's unique capabilities in navigating the complexities of the extracellular matrix provide a number of exciting opportunities to build shareholder value," said Jonathan Lim, MD, Halozyme's President and CEO. "Building on our track record for accelerated development and commercialization and leveraging the franchises of our partners, we continue to pursue these opportunities by executing our Enable, Improve and Innovate programs. The Enable program focuses on making our partners' drugs better by potentially improving administration, extending product lifecycles, and increasing patients' compliance, and includes HYLENEX recombinant (hyaluronidase human injection) and our Enhanze(TM) Technology for drug delivery. In this regard, we are very pleased that we recently broadened our relationship with Baxter to apply our Enhanze Technology to their GAMMAGARD product. We are also excited about developing our own products through the Improve program, which focuses on co-formulations of rHuPH20 with marketed small molecules, particularly oncology and bisphosphonate drugs; and the Innovate program, which focuses on developing new molecular entities targeting the extracellular matrix with some exciting projects underway in oncology and dermatology."

Third Quarter 2007 Highlights

-- The completion of a new agreement with Baxter International Inc. to

a
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
(Date:12/17/2014)... 17, 2014 This report is ... Tubing industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry has witnessed rapid development with key ... acquisitions. This report mentions quartz tubing upstream raw ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... CALUIRE, France, Feb. 19 Setaram,Inc., a ... announces the acquisition of Hy-Energy LLC (Newark, ... scientific instruments for,the ever-expanding field of clean ... a full suite of analytical capabilities which,complement ...
... 19 Barr Pharmaceuticals,Inc. (NYSE: BRL ) ... received final approval from the U.S. Food and ... Ingelheim,Pharmaceuticals, Inc.,s Mirapex(R) Tablets (Pramipexole Dihydrochloride),0.125mg, 0.25mg, 0.5mg, ... is the,first to file an Abbreviated New Drug ...
... Technology Providers Broadens ... Opportunities for Distribution, New Markets, SILVER SPRING ... and Immersion Medical, a subsidiary of Immersion Corporation,announced ... enhanced version of B-Line Medical,s SimCapture(TM) product. SimCapture,is ...
Cached Biology Technology:Setaram Inc. Acquires Hy-Energy LLC 2Barr Receives Final Approval for Generic Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg 2Barr Receives Final Approval for Generic Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg 3Barr Receives Final Approval for Generic Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg 4B-Line Medical and Immersion Medical Announce Partnership 2B-Line Medical and Immersion Medical Announce Partnership 3
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... are developing a cost-effective electronic monitoring system that will ... ecosystems by allowing users to track water-quality data from ... a National Science Foundation (NSF) grant. "Our goal ... environmental conditions in the Chesapeake Bay, the sounds of ...
... to help the government cut through red tape and roll ... This week, the university,s Durham Energy ... meet with the Department of Energy & Climate Change to ... on Wednesday November 3rd will also be attended by Ofgem ...
... Calif., Nov. 1, 2010 General Manifolds LLC, a ... that the United States Patent and Trademark Office has ... method for simulating functions within the cerebral cortex of ... a broad range of applications from artificial intelligence to ...
Cached Biology News:Researchers developing real-time electronic monitoring for coastal waters 2Durham Energy Institute to advise government on green technology 2General Manifolds LLC Announces Issuance of US Patent in Computational Neuroscience 2
... 500 Series is a sophisticated ... most advanced technologies available. The ... testing, powerful software and a ... researchers optimize their overall workflow ...
... of a protein into cells permits studies ... pathways, apoptotic pathways, and transcription factor-mediated gene ... the effects of a specific protein in ... protein directly into the cell. ProteoJuice Protein ...
Reacti-Bind DNA Coating Solution...
Immunogen GST fusion protein corresponding to full-length rat JNK3/ SAPK1b. Quality Assurance Routinely evaluated by immunoblot. Stability 2 years at -20°C from date of shipment GenBank A...
Biology Products: